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Smoking is an important cardiovascular risk factor, however, use of smokeless tobacco has
not been well studied. Smokeless tobacco use is high in countries of South and Southeast
Asia, Africa and Northern Europe. Meta-analyses of prospective studies of smokeless to-
bacco users in Europe reported a relative risk for fatal coronary heart disease of 1.13
(confidence intervals 1.06e1.21) and fatal stroke of 1.40 (1.28e1.54) while in Asian countries
it was 1.26 (1.12e1.40). Case-control studies reported significantly greater risk for acute
coronary events in smokeless tobacco users (odds ratio 2.23, 1.41e3.52), which was lower
than smokers (2.89, 2.11e3.96), and subjects who both chewed and smoked, had the
greatest risk (4.09, 2.98e5.61). There is a greater prevalence of hypertension and metabolic
syndrome in users of smokeless tobacco. Smokeless tobacco use leads to accelerated
atherothrombosis similar to smoking. There is an urgent need for public health and clinical
interventions to reduce smokeless tobacco addiction.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction we describe the epidemiology of smokeless tobacco use withSmoking is the most reliably documented cardiovascular risk
factor.1 Historical trends in cardiovascular disease (CVD)
mortality and smoking in the United States from 1900 to 1990
closely mirror each other, with both rates increasing through
the 1950s, followed by a precipitous fall beginning in the
1960s.2 There is a strong epidemiological, experimental, clin-
ical and randomized controlled trial evidence of support for
smoking as important CVD risk factor.3 Prevalence of smoking
has declined in most high income countries.4 On the other
hand, in manymiddle and low income countries, especially in
South and Southeast Asia, smoking as well as use of smoke-
less tobacco is increasing.5 CVD risks associated with
smokeless tobacco use are not well described. In this review,.
, rajeevgg@gmail.com (R.
2013, Cardiological Societfocus on low and middle income countries and its association
with CVD and CVD risk factors.2. Epidemiology of smokeless tobacco use
Smoking and tobacco use is a worldwide health problem
(Fig. 1).1,6 Use of smokeless tobacco predates smoking. Initial
descriptions are available from the American continents in
middle of second millennium.7 Native Americans in North
and South America chewed the leaves of the plant, frequently
mixed with the mineral lime. Chewing tobacco was the most
prevalent form of tobacco use in the United States until it was
overtaken by cigarette smoking in the early 20th century.7Gupta).
y of India. All rights reserved.
Fig. 1 e Smoking and tobacco use among adults in different regions of the world. Adopted from WHO.1
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chewing or sniffing and contains several carcinogenic com-
pounds.1 Smokeless tobacco has been associated with oral
cancer, hypertension, heart disease and other conditions.1
Smokeless tobacco may also refer to tobacco dipping, snuff,
snus, creamy snuff or tobacco toothpaste, tobacco gum,
dissolvable tobacco, topical tobacco paste, tobacco water,
herbal smokeless tobacco, etc. Smokeless tobacco use is more
prevalent in countries of Asia, Africa and the Middle East than
in Europe and the Americas.7 Data on these forms of tobacco
use are not readily available for most parts of the world.
Prevalence of smokeless tobacco use has been studied in
high income countries and reports a low prevalence. Behav-
iour Risk Surveillance System Study reported smokeless to-
bacco use in USA.8 The use ranged from 1-9% in different
states and was more in younger men with low educational
status, and in states with high smoking prevalence. The US
Current Population Survey9 reported a significant decline in
smokeless tobacco use from 1992 to 2002. The US National
Health Interview Surveys (1991e2003)10 also reported decline
in smokeless tobacco use. Prevalence of smokeless tobacco
use has also been reported from European countries. It is
almost similar to USA with rates ranging from 1-9% in
different countries.1 The Global Adult Tobacco Survey, 2009
reported that in Russian Federation, 0.6% (0.7 million) of adult
population used smokeless tobacco. Prevalence was more
among males (1.0%) than among females (0.2%) and higher in
urban areas (0.7%) as compared to rural areas (0.3%).12.1. Middle and low income countries
In contrast to the United States and Western European
countries, smokeless tobacco use is high in Northern Euro-
pean and African countries and in Asia.1,11 In India, 22% of
men and 17% of women use smokeless tobacco, in Sudan 40%
of men and 10% women use toombak, a locally brewed
smokeless tobacco, and in Sweden among those >16 years of
age 21.2% of men and 3.9% women use snus.1,11
The WHO Southeast Asian Region is the hub of smokeless
tobacco users.12 It has a history of people using different
smokeless tobacco products for centuries. Decades ago,
people used only locally made smokeless tobacco products
such as betel quidwith tobacco. However, in recent timeswith
large-scale production of tobacco, varieties of manufactured
products have become widely available to the people in this
region. It is home to nearly 250 million smokeless tobacco
users.12,13 Chewing, sucking and applying tobacco prepara-
tions are common ways of using tobacco orally. The simplest
form of smokeless tobacco product is a betel quid, where to-
bacco is added to the betel leaf and areca nutwith some slaked
lime. It is commonly available and has been in use for many
years in Bangladesh, India, Myanmar and Nepal. Prevalence of
smokeless tobacco among men in the Southeastern countries
ranges from 1.3% in Thailand to 51% in Myanmar.12 Among
women, it ranges from 4.6% in Nepal to 27.9% in Bangladesh.12
Use of smokeless tobacco products among male students in
this region aged 13e15 years ranged from 3.3% in Indonesia to
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 3 6 9e3 7 7 37143.2% in Timor-Leste, and among females from 2.3% in
Indonesia to 40.7% in Timor-Leste.1 Some sub-national sur-
veys show that working children and street children are far
more likely to use tobacco than students.1
In India, tobacco consumption is mainly in two forms:
smoked tobacco products and smokeless tobacco.13 Most
commonly used smokeless tobacco products include e to-
bacco pan masala, tobacco with lime, tobacco with pan and
betel quid. According to a recent report, the prevalence of
smokeless tobacco consumption in India is 20%.12 It is
significantly higher in males than in females (28% in males
and 12% in females), and in rural population as compared to
urban population.13 Third National Family Health Survey in
India (2005e2006) reported 34% prevalence of chewable
smokeless tobacco use in men 15e54 years.14,15 Easy afford-
ability, lesser cost and misconceptions regarding its useful
health effects are important contributory factors for increased
smokeless tobacco consumption. Tobacco consumption is
higher among poor, less educated, scheduled castes and
scheduled tribes. Global Adult Tobacco Survey e India report
mentions a high use of smokeless tobacco among men and
women aged >15 years in India.1 A sample of almost 800,000
men and women was evaluated for habit of tobacco use and
data showed that almost a quarter (26%) of all adults in India
use smokeless tobacco either by chewing, sniffing or applying
to teeth or gums. Use of smokeless tobacco was more preva-
lent than smoking and wasmore inmen (33%) than in women
(18%).1 WHO Global Health Observatory Data Repository has
reported prevalence of smokeless tobacco use among adults
in 2008 (Table 1).16 The use is significantly greater amongmen
than in women in almost all the countries. Prevalence is
greater in low income countries. There are limited studies in
Africa. A study in Nigeria reported 7.5% prevalence of
smokeless tobacco use with the most common form being
snuff.17
Smokeless tobacco use is an important health issue among
children and youth in low income countries. Global school
based health surveys in the year 2006 among 44 countriesTable 1 e Smokeless tobacco use among adults in
selected countries according to WHO Global Health
Observatory Data Repository (2008) and Global Adult
Tobacco Survey India (2010).21,22
Country Men
(%)
Women
(%)
Total
(%)
High income countries
Denmark 1.9 0.5 1.2
Sweden 7.0 3.0 e
Middle income countries
Malaysia 0.5 3.1 0.6
Uzbekistan 22.5 0.4 11.3
South Africa 2.4 10.9 e
Yemen 15.1 6.2 10.7
Low-middle/low income countries
Bangladesh 14.8 24.4 19.7
Cambodia 17.0 1.0 10.1
India 32.9 18.4 25.8
Nepal 31.2 4.6 18.6across 110 sites reported a substantial variation in non-
cigarette forms of tobacco use, which include smokeless to-
bacco from a low of 1.0% in China to 43.7% in Northwest
Namibia.18 Global Tobacco Surveillance System reported pat-
terns of tobacco use among nearly 750,000 youth, aged 13e15
years at more than 10,000 schools and 395 sites in 131 coun-
tries.19 The use of non-cigarette forms of tobacco use, which
include smokeless tobacco (11.2%), was more than smoking
(8.9%). The rates were the highest in Southeast Asia (13.3%)
and the Eastern Mediterranean region (12.9%) and were less
than 10% in the Western Pacific and European regions.19
Anecdotal evidence suggests that smokeless tobacco use,
among the youth has increased exponentially in India
(Table 2).20 Project MYTRI, a cross-sectional study conducted
in India (Delhi and Chennai), reported higher levels of
smokeless tobacco use among 6th grade students than 8th
graders. This suggested increased tobacco use among younger
children in India.21
Trends in prevalence of smokeless tobacco use have not
been well studied in low income countries. In India, the Na-
tional Family Health Surveys from 1992 to 2006 did not report
significant changes in smoking or smokeless tobacco use.22 A
study among urban subjects in Northwest India reported
declining trends in smoking among men and women over a
20-year-period (1991e2010) but trends in smokeless tobacco
use were not reported.233. Smokeless tobacco and cardiovascular
disease
There are several adverse health effects attributable to
smokeless tobacco.24e26 Similar to smoked tobacco, the
smokeless tobacco also contains nicotine, a chemical with
addicting properties. Unfortunately, people are not aware of
the addiction potential of smokeless and other forms of to-
bacco.24 They are also unable to stop its use once addicted
because of unpleasant withdrawal symptoms. Smokeless
and other tobacco products are known to cause oral, pancre-
atic, pharyngeal, esophageal and stomach cancers.26 Some
studies also show that smokeless tobacco users die of CVD
and other circulatory diseases.24 Low birthweight and still-
births are two major adverse reproductive outcomes found in
association with its use in pregnancy.27
Association of smokeless tobacco consumption with
occurrence of adverse cardiovascular events like myocardial
infarction, stroke, and ischemic heart disease has been stud-
ied in detail in western population.24 Results from these
studies paint a mixed picture with some showing increased
incidence of these events while others showing no such as-
sociation. Similarly, contradictory results have been seen in
studies evaluating increased risk factors for CVD in smokeless
tobacco consuming population.
3.1. Prospective studies
There are limited prospective studies that assessed role of
smokeless tobacco on CVD outcomes or mortality.24 Most of
these studies have been performed in Northern Europe. Re-
sults on the risk for myocardial infarction or stroke have
Table 2eNon-cigarette forms of tobacco usewhich include smokeless tobacco among adolescents in Global Youth Tobacco
Survey e 1999e2005 (Percent, 95% confidence intervals).25
Region Total Boys Girls
Total 11.2 (9.7e12.7) 13.8 (11.7e15.9) 7.8 (6.0e9.6)
African region 10.5 (8.3e12.7) 10.9 (8.0e13.8) 9.9 (7.3e12.5)
Americas region 11.3 (9.8e12.8) 14.8 (12.6e17.0) 7.8 (6.2e9.4)
Eastern Mediterranean region 12.9 (10.6e15.2) 15.6 (12.4e18.8) 9.9 (7.3e12.5)
European region 8.1 (5.8e10.4) 10.0 (6.7e13.3) 6.0 (4.0e8.0)
Southeastern Asian region 13.3 (12.3e14.3) 16.4 (15.0e17.8) 8.4 (6.8e10.0)
Western Pacific region 6.4 (5.2e7.6) 7.7 (6.1e9.3) 5.4 (3.9e6.9)
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formed a meta-analysis of studies of association of smoke-
less tobacco use and CVD.28 Very few studies were identified;
only three from Sweden considered CVD outcomes and the
results were discrepant. There was a modest association
between the use of Swedish snuff (snus) and CVD (relative
risk 1.4, 95% confidence interval 1.2e1.6 in one prospective
cohort study). Several other studies have considered associ-
ations between smokeless tobacco use and intermediate
outcomes (CVD risk factors).24 It was concluded that there
may be an association between smokeless tobacco use and
CVD, however, further rigorous studies with adequate sam-
ple sizes were required.
Boffetta and Straif also performed ameta-analysis of these
studies.29 In all, eight studies that evaluated risk of fatal
myocardial infarction and five studies that evaluated fatal
stroke were analyzed. Three studies showed increased risk for
cardiovascular deaths (fatal myocardial infarction and stroke)
when compared to non-smokers, while others did not show
any significant difference in outcomes (Fig. 2). The summary
odds ratio (OR) statistic and 95% confidence intervals (CI) show
greater risk of fatal myocardial infarction (OR 1.13, 95% CI
1.06e1.21) and fatal stroke (OR 1.40, 95% CI 1.28e1.54). A
population based prospective study in Sweden reported that
among snuff users the risk of myocardial infarction (OR 0.82,
95% CI 0.46e1.43) or sudden cardiac death (OR 1.18, 95% CI
0.38e3.70) was not significant.30
Studies in low and middle income countries of Asia and
Africa have been few. Gupta et al performed a prospective
study involving about 100,000 men and women in Mumbai,
India.31 At follow-up of five years, relative risk of fatal car-
diovascular event among male users of smokeless tobacco
was not significantly different from non-tobacco users. In
women, smokeless tobacco use was associated with signifi-
cantly greater risk of cardiovascular mortality (Fig. 3). Zhang
et al performed a meta-analysis of studies on association of
smokeless tobacco use and cardiovascular outcomes in
Asia.32 Studies from China, Taiwan and India were included
(Fig. 4). The study reported insignificant association of to-
bacco use and cardiovascular mortality in India but the
relationship was significant in studies in China and
Taiwan.32 The summary odds ratio was 1.26 (95% CI
1.12e1.40), which indicated moderate risk of cardiovascular
death with smokeless tobacco use. Thus, use of smokeless
tobacco (with snuff being the most studied variant) involves
a much lower risk for adverse cardiovascular effects than
smoking.3.2. Association studies
There are limited case-control studies that evaluated cardio-
vascular risks in smokeless tobacco users as compared to non-
users. Two case-control studies from Sweden showed the
same cardiovascular risks among smokeless tobacco users as
in non-tobacco users.33,34 The odds ratios for all and fatal
myocardial infarction remained non-significant after adjust-
ments for various potential confounders.
INTERHEART study evaluated 27,089 participants for as-
sociation of cardiovascular risk factors with acute myocar-
dial infarction in 52 countries (12,461 cases, 14,637
controls).35 Relationship between risk of myocardial infarc-
tion with current or former smoking, type of tobacco,
smokeless tobacco use and exposure to second hand tobacco
smoke was determined. Current smoking was associated
with a greater risk of non-fatal myocardial infarction (OR
2.95, 95% CI 2.77e3.14) compared with never smoking.
Smoking beedies alone (indigenous to South Asia) was
associated with increased risk (OR 2.89, 95% CI 2.11e3.96)
similar to that associated with cigarette smoking. Chewing
tobacco alone was associated with OR 2.23 (95% CI 1.41e3.52),
and smokers who also chewed tobacco had the highest risk
(OR 4.09, 95% CI 2.98e5.61) of acute myocardial infarction.
Similar results have been reported by smaller case-control
studies.244. Smokeless tobacco and cardiovascular
risk factors
In high income countries, there have been studies to deter-
mine association of smokeless tobacco use and cardiovascular
risk factors.24 Older studies among young Swedish snuff-
using subjects36 or US professional baseball players37 did not
report any significant association. A study among 58-year old
men reported significantly greater waist-size, triglycerides
and other manifestation of dysmetabolic syndrome in
smokeless tobacco users.38 This was confirmed in a prospec-
tive Swedish study, which showed that over a period of 10
years, high dose consumption of snus was associated
with development of metabolic syndrome (OR 1.6, 95% CI
1.26e2.15).39
Prospective studies that evaluated development of other
cardiovascular risk factors have also been performed. Hergens
et al performed a cohort study with 15 year follow-up of a
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Fig. 2 e Smokeless tobacco use and risk of fatal myocardial infarction (upper graph) or fatal stroke (lower graph) in high
income countries. Summary meta-analysis odds ratio statistic and 95% confidence intervals (CI) show greater risk of fatal
stroke (1.40, CI 1.28e1.54) as compared to fatal myocardial infarction (1.13, CI 1.06e1.21). Data source: Boffetta & Straif. BMJ,
2009.29
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Blood pressure (BP) was measured at baseline and at follow-
up. As compared to non users (n ¼ 4815), men who used
snuff regularly (n ¼ 1010) had an increased relative risk of
hypertension of 1.43 (95% CI 1.12e1.83). In a population based
cross-sectional study of >30,000 participants in Sweden,
smokeless tobacco users were 1.8 times (95% CI 1.5e2.1) more
likely to have a diastolic BP reading more than 90 mmHg and0.5
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Fig. 3 e Smoking, smokeless tobacco use and
cardiovascular mortality in India: Mumbai Cohort Study.
Smokeless tobacco use in women is significantly
associated with cardiovascular mortality (relative risk 1.19,
95% CI 1.02e1.38) while the association is not significant in
men (relative risk 0.94, 95% CI 0.82e1.09). Data source:
Gupta, et al. Int J Epidemiol, 2005.311.7 times (95% CI 1.3e2.1) more likely to have a systolic
BP > 160 mmHg.41
Several studies in Sweden have examined the effect of
smokeless tobacco products on serum lipids.24 No significant
effects were found in levels of total cholesterol and HDL
cholesterol among snuff users compared to controls in these
populations. On the other hand, Tucker et al from a large
population based study reported that subjects who used
smokeless tobacco had 2.5 times greater prevalence of0
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Fig. 4 e Smokeless tobacco use and cardiovascular
mortality in Asian countries. Studies from China, Taiwan
and India have reported significant association of tobacco
use and cardiovascular mortality in cohort studies.
Summary odds ratio (1.26, CI 1.12e1.40) indicates
moderate risk. Data source: Zhang, et al. J Zhejiang Univ
Sci, 2010.37
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 3 6 9e3 7 7374hypercholesterolemia.42 Khurana et al reported significantly
lower levels of HDL cholesterol and greater levels of LDL
cholesterol in Asian Indian subjects who chewed tobacco
regularly.43 In another study of 3128 men, there was higher
prevalence of diabetes among long-term users of smokeless
tobacco (OR 2.7, 95% CI 1.3e5.5).44 Abnormalities of platelet
function, oxidative stress and coagulation factors have also
been evaluated among smokeless tobacco users.24 No signifi-
cant differences have been reported as compared to non-users.
To identify cardiovascular risk factors among tobacco chewers,
Gupta et al performed a population based case-control study in
India.45 Tobacco chewers had a significantly greater preva-
lence of resting tachycardia, hypertension, hypercholester-
olemia, low HDL cholesterol, hypertriglyceridemia and
diabetes compared to non-smokers/non-tobacco users (Fig. 5).
The risk factors were similar to smokers (Fig. 5).
Smoking is a well-established CVD risk factor.24,46 Ciga-
rette smoking leads to acute coronary thrombosis and
chronically produces endothelial dysfunction, hypercoagula-
bility and inflammation, resulting in accelerated atheroscle-
rosis.46 Smoking also leads to a wide variety of mechanistic
disruptions e platelet activation and thrombogenesis, endo-
thelial dysfunction, accelerated atherogenesis, inflammation,
sympathoadrenal activation, arrhythmogenesis, insulin resis-
tance and hyperlipidemia e all of which can contribute to
CVD. It has been suggested that smokeless tobacco produces
vascular damage through similar biological mechanisms.24,46
More studies are required to elicit pathophysiological mech-
anisms of smokeless tobacco on vascular system, thrombosis
and atherosclerosis.5. Public health implications
A concept on implementing state policy on combating tobacco
for 2010e2015 was developed byWHO and approved for use in40
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Fig. 5 e Cardiovascular risk factors in smokers, smokeless
tobacco users and non-tobacco users in India. Greater
prevalence of hypertension, hypercholesterolemia, low
HDL cholesterol, hypertriglyceridemia and diabetes is
observed among smokeless tobacco users vs non-tobacco
users (p< 0.05). Prevalence of risk factors is similar to
smokers. Data source: Gupta, et al. J Assoc Physicians
India, 2007.45the WHO Framework Convention on Tobacco Control (FCTC)
and MPOWER policy package.1 The features include (i) to
continue working on tobacco control awareness programs
where all subpopulations have equal access to the activities
and information; (ii) public health policy and interventions
should cover all types of tobacco products; (iii) periodic
monitoring of tobacco use through standard surveys should
be continued and integrated into tobacco control action plans
and existing health systems to implement the concept of
WHO FCTC.1 Government of India and many state govern-
ments have implemented some aspects of FCTC. Tobacco
taxations are being raised regularly.47 A notification of Food
Safety and Standards Authority of India has prohibited the use
of tobacco and nicotine in any food product.48 However, in-
dicators for smokeless tobacco were not included in the
package. Smokeless tobacco is now exported to many coun-
tries and available in local brands. With increased availability
of smokeless tobacco products globally, these tobacco control
strategies need to be revisited and regulation and control of
smokeless tobacco products needs to be emphasized. Regional
efforts on curbing smokeless tobacco should be included in
the tobacco control policies.
There is also a need to build capacity for programs among
healthcare providers and expand cessation services in the
national health programs.1 The following action items have
been recommended: (i) strengthen the national health system
to provide smoking and non-smoked tobacco use cessation
services in primary healthcare facilities; (ii) introduce
evidence-based smoking cessation and non-smoked tobacco
control approaches and interventions; (iii) formulate a 100%
tobacco-free policy for all public places and workplaces to
meet the expectations of population; (iv) gradually raise taxes
on all types of tobacco products, given the high prevalence of
non-smoked tobacco use and the low price of smokeless to-
bacco products compared to increases in income; (v) expand
the national tobacco control act to include smokeless tobacco
under the purview of tobacco control at par with all smoking
tobacco products with the purpose to prevent the use of
smokeless tobacco and any other new tobacco and nicotine
products; (vi) continue working with mass media on effective
anti-smoking and anti-tobacco use media messages that
target specific demographic groups; (vii) further develop the
health warnings on tobacco products, as health warnings are
one of the most effective methods for encouraging tobacco
users to quit; (viii) decrease the number and regulate the type
of venues where tobacco products can be sold; and (ix)
gradually prohibit tobacco advertising at points of sale, as a
high percentage of cigarette smokers and non-smoked to-
bacco users notice advertisements where they purchase
them. At the individual level, whether or not the apparent
risk reduction is a useful strategy to help inveterate tobacco
users to quit is a matter of debate, as are the public health
effects of a high prevalence of smokeless tobacco use in some
populations.
TheUSNational Institutes ofHealth has also recommended
strategies for tobacco control and focussed on smokeless to-
bacco use (Table 3).49 The key strategies include population-
and community-based interventions, increasing consumer
demand for cessation treatments, promoting implementation
of the existing strategies by healthcare system as well as
Table 3 e Strategies for smokeless tobacco control.
Strategies Actionable items
Population- and community-based interventions  Increased prices through taxation on tobacco products
 Laws and regulations that prevent young people from gaining access
to tobacco products
 Restrict tobacco advertising
 Mass media campaigns
Increasing consumer demand for proven
cessation treatments
 Proactive telephone tobacco cessation support
 Healthcare provider advise to stop tobacco use
 Educational approaches
 Pharmacological therapies, e.g., bupropion
 Increase in price of tobacco products
 Reducing out-of-pocket costs of cessation therapies
 Culturally tailored, gender-specific, language appropriate programs
Promoting implementation of strategies by
healthcare systems and communities
 Healthcare system level interventions for tobacco use cessation
 Financial incentives
 Health system level educational and organizational approaches
 Dedicated staff for tobacco cessation services
Control of marketing of smokeless tobacco
products
 Control of availability of these products
 Inexpensive pharmacological and behavioral cessation therapies
Prevention and cessation interventions in
populations with co-morbidities and risk
behaviors
 Tailored multimodal cessation interventions
 Proper timing of initiation of interventions
Public health efforts and future research  Improve and implement effective interventions
 Improve and implement effective policies
 Develop new population- and community-based interventions
 Smokeless tobacco pathophysiological, behavioral, and intervention
research
 Infrastructure development
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 3 6 9e3 7 7 375communities, control of marketing of smokeless tobacco
products, and accelerated public health efforts and promotion
of future research. It is essential to integrate worldwide health
promotion agencies to support smokeless tobacco control
programs. At the population level, tobacco control policies
should be integrated into the overall health and development
agenda.50 This should involve integration of tobacco control
into broader health and development agenda such as food and
water security, environment, the right to educationandhuman
rights. Policy and administrative integration of tobacco and
other primordial determinants of cardiovascular health
(physical activity promotion, alcohol control and promotion of
healthy diet)51 shall encourage a holistic solution to CVD and
non-communicable diseases.6. Conclusions
This review shows that smokeless tobacco use is an important
public health problem. Prevalence is high in low income
countries and the highest in South Asia and Southeastern
Asian regions. Prospective studies have reported a significant
association of smokeless tobacco use with cardiovascular
mortality (coronary heart disease and stroke) as well as acute
coronary events. Smokeless tobacco use is associated with
increased cardiovascular risk factors such as the metabolic
syndrome and diabetes. Mechanistic issues that lead to an
increased cardiovascular risk of smokeless tobacco needmore
studies. There is a need for population- and community-wide
policy interventions for smokeless tobacco control. Individual
interventions promoting tobacco cessation are important. Werecommend a worldwide ban on smokeless tobacco products
to attenuate multiple harms, including CVD, associated with
its use.Conflicts of interest
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